CD Antigens
CD Antigens(CD抗原)
Cell surface antigens of leukocytes are called CD antigens, and important for immune reactions of organisms. As lymphocytes mature, they express different protein receptors on the cell surface, which can aid in determining the type and maturation stage of the cells being examined. These proteins or antigen markers are called Clusters of Differentiation
The term CD means a cluster of differentiation OR a cluster of determinants which indicates the lineage or maturational stage of lymphocytes. During the course of development from precursor cells into functionally mature forms, lymphocytes display a complex pattern of surface antigens, some of which are acquired at certain stages while others are lost.
These surface antigens were identified initially by monoclonal antibodies and the designations of the antibodies were used often as synonyms for the cell surface proteins they detected, giving rise to a plethora of different names. CD antigens are present on some subpopulations and functional types of leukocytes. CD antigens participate in immune reaction as receptors for cell communication (e.g. adherence molecules, antigen recognizing receptors).
CD antigen nomenclature describes different monoclonal antibodies from different sources that recognize identical antigens. Numbers are assigned arbitrarily. A small letter w before the number designation stands for "workshop". It indicates that the CD designation is tentative.
CD antigens are found on practically all known cell types. In some cases CD antigens are expressed only at certain stages of development or under certain conditions, for example after cell activation or in certain disease conditions. In Hematology the morphological criteria is for the description of specific developmental stages of lymphocytes unlike in CD antigens which the use of monoclonal antibodies allows the objective and precise analysis and standardized typing of mature and immature normal and malignant cells of all hematopoietic cell lineages. The use antibodies also helps to delineate the biologic traits that distinguish normal immune and hematopoietic cells from their malignant counterparts, which is utmost important in the understanding of hematological malignancies.
The expression of CD antigens is influenced by cytokines, such as binding of ligands to CD antigens which has shown to modulate the expression of cytokines. CD antigens have been shown to be identical with receptors of cytokines such as CD25 (TAC antigen).
CD antigens appear to carry out cytokine receptor-like functions such as CD27, CD30 and CD40. CD antigens are involved in modulating the biological activities of cytokines such as CD4, CD28 and CD40. CD antigens exist also in soluble forms for example CD14, CD21, CD23, CD27, CD100 and CD137.
The CD Antigen’s designation isn’t related to the biological function, thus CD antigens include receptors, glycans, adhesion molecules, membrane-bound enzymes, etc.
The most commonly know CD antigens are CD4 and CD8 which are markers for T-helper and T-suppressor cells, respectively. CD4 binds to relatively invariant sites on class II major histocompatibility complex molecules outside the peptide-binding groove, which interacts with the T-cell receptor. CD4 is also the central docking receptor for human immunodeficiency virus. CD8 binds to relatively invariant sites on class I major histocompatibility complex molecules outside the peptide-binding groove. CD8 is also expressed on a subset of dendritic cells. Other more important CD antigens include the leukocytes integrins (CD11/CD18) and the hematopoietic stem cell marker CD34.
CD69 is homologous to members of a supergene family of type II integral membrane proteins having C-type lectin domains. Although the precise functions of the CD-69 antigen is not known, evidence suggests that these proteins transmit mitogenic signals across the plasma membrane and are up- regulated in response to lymphocyte activation
In the last decade the wide palette of monoclonal antibodies has been prepared which recognise of CD antigens on human cells. Much less monoclonal antibodies are available specific for typing of domestic animal cells. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI).
- CD1(4)
- CD14(5)
- CD164(2)
- CD2(5)
- CD200(5)
- CD204(2)
- CD207(2)
- CD226(2)
- CD23(2)
- CD244(2)
- CD247(2)
- CD27(3)
- CD274(3)
- CD3(28)
- CD300(4)
- CD33(2)
- CD34(3)
- CD36(2)
- CD4(5)
- CD40(2)
- CD46(2)
- CD47(7)
- CD5(2)
- CD55(2)
- CD58(2)
- CD5L(3)
- CD68(3)
- CD7(2)
- CD73(12)
- CD74(2)
- CD79(3)
- CD80(1)
- CD84(2)
- CD8B(2)
- CD93(2)
- CD99(2)
- Fc Fragment of IgG Receptor(6)
- Other CD Antigens(46)
- sCD40L(5)
- LAG-3(3)
- Mucin(4)
- CD38(2)
- CD19(1)
CD Antigens 相关产品(200)
- GC62695OP-5244 sodium
OP-5244 sodium 是一种有效和具有口服活性的 CD73 抑制剂,IC50 值为 0.25 nM。OP-5244 sodium 通过阻断腺苷的产生来逆转免疫抑制作用,具有进行癌症研究的潜力。
- GC68344MupadolimabCAS: 2451856-97-4
Mupadolimab (CPI-006) 是一种 IgG1κ 人源化的 FcγR 结合缺陷抗 CD73 单抗,激活 CD73POS B 细胞。
- GC68346UliledlimabCAS: 2378407-27-1
Uliledlimab 是一种有效的抗 CD73 人源单克隆抗体。Uliledlimab 抑制胞外单磷酸腺苷 (AMP) 向腺苷的转化。Uliledlimab 可用于癌症的研究。
- GC68858CevostamabCAS: 2249888-53-5纯度: >95.00%
Cevostamab (BFCR4350A; RG6160; RO7187797) 是一种人源化、基于 IgG1 的 BsAb,可靶向多发性骨髓瘤 (MM) 细胞上 FcRH5 的近膜端胞外结构域,以及 T 细胞上的 CD3。此外,Cevostamab 促进有效突触的形成,提高 T 细胞对 MM 肿瘤细胞的杀伤活性。
- GC69453MethADP triammonium纯度: >99.00%
MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium 是一种 CD73 抑制剂。MethADP 可用于 ATP-腺苷通路的研究。
- GC69894SiplizumabCAS: 288392-69-8
Siplizumab (MEDI-507) 是一种抗 CD2 的人源化 IgG1 单克隆抗体。Siplizumab 可耗尽 T 细胞、降低 T 细胞活化、抑制 T 细胞增殖并富集 naÏve 和 bona fide 调节性 T 细胞。
- GC69985TalquetamabCAS: 2226212-40-2纯度: >96.00%
Talquetamab(JNJ-64407564)是一种人源化的双特异性抗体,可与 GPRC5D (G 蛋白偶联受体家族C5组成员 D) 和 CD3 结合,通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab(JNJ-64407564)具有抗肿瘤活性。
- GC70011TeplizumabCAS: 876387-05-2纯度: >99.00%
Teplizumab (MGA-031) 是一种 Fc 受体型、非结合类型的抗-人 CD3 的单克隆抗体。Teplizumab 可缓解 β 细胞的功能丧失。Teplizumab 可用于 type 1 型糖尿病的研究。
- GC72443PavurutamabCAS: 2250292-39-6纯度: >95.00%
Pavurutamab (AMG-701)是一种抗cd3和抗b细胞成熟抗原(BCMA)的双特异性T细胞接合分子。
- GC73334Glutaminyl cyclases-IN-1CAS: 3032400-33-9纯度: >98.00%
Glutaminyl cyclases-IN-1(IsoQC-IN-1)是一种强效的谷氨酰胺环化酶(QC)抑制剂,对人类QC和IsoQC的IC50值分别为12 nM和73 nM。
- GC74428AnzurstobartCAS: 2543693-10-1纯度: >98.00%
Anzurstobart (cc - 95251;BMS-986351)是一种高亲和力的全人源单克隆抗SIRPα抗体,可阻断CD47与SIRPα的结合。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC62331 | CD73-IN-3 | 2375815-63-5 | >99.50% | |
LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase). | ||||
| GC62452 | CD73-IN-4 | 2216764-29-1 | >99.50% | |
CD73-IN-4 是一种高效、选择性的亚甲基膦酸 CD73 抑制剂,对人 CD73 作用的 IC50 值为 2.6 nM。CD73-IN-4 在癌症免疫学研究中具有潜在的应用价值。 | ||||
| GC62694 | OP-5244 | 2381268-71-7 | >99.50% | |
OP-5244 是一种有效和具有口服活性的 CD73 抑制剂,IC50 值为 0.25 nM。OP-5244 通过阻断腺苷的产生来逆转免疫抑制作用,具有进行癌症研究的潜力。 | ||||
| GC62695 | OP-5244 sodium | - | - | |
OP-5244 sodium 是一种有效和具有口服活性的 CD73 抑制剂,IC50 值为 0.25 nM。OP-5244 sodium 通过阻断腺苷的产生来逆转免疫抑制作用,具有进行癌症研究的潜力。 | ||||
| GC65293 | AB-680 | 2105904-82-1 | >98.00% | |
AB-680 是一种有效、可逆、选择性的 CD73 (胞外核苷酸酶) 抑制剂,对 hCD73 的 Ki 值为 4.9 pM,对其选择性是对相关胞外核苷酸酶 CD39 的 10000 多倍。具有抗肿瘤活性。 | ||||
| GC65470 | Oleclumab | 1803176-05-7 | >98.00% | |
Oleclumab (MEDI9447) 是一种人 IgG1Λ 抗 CD73 单克隆抗体,可抑制 CD73 功能。Oleclumab 具有抗肿瘤活性。 | ||||
| GC68344 | Mupadolimab | 2451856-97-4 | - | |
Mupadolimab (CPI-006) 是一种 IgG1κ 人源化的 FcγR 结合缺陷抗 CD73 单抗,激活 CD73POS B 细胞。 | ||||
| GC68346 | Uliledlimab | 2378407-27-1 | - | |
Uliledlimab 是一种有效的抗 CD73 人源单克隆抗体。Uliledlimab 抑制胞外单磷酸腺苷 (AMP) 向腺苷的转化。Uliledlimab 可用于癌症的研究。 | ||||
| GC68386 | CD73-IN-5 | 2412019-99-7 | - | |
CD73-IN-5 是一种有效且选择性的非核苷酸小分子 CD73 抑制剂(IC50 = 19 nM)。 | ||||
| GC68858 | Cevostamab | 2249888-53-5 | >95.00% | |
Cevostamab (BFCR4350A; RG6160; RO7187797) 是一种人源化、基于 IgG1 的 BsAb,可靶向多发性骨髓瘤 (MM) 细胞上 FcRH5 的近膜端胞外结构域,以及 T 细胞上的 CD3。此外,Cevostamab 促进有效突触的形成,提高 T 细胞对 MM 肿瘤细胞的杀伤活性。 | ||||
| GC69127 | Foralumab | 946415-64-1 | - | |
Foralumab (NI-0401) 是一种口服有效的人源化单克隆抗体,靶向 CD3。Foralumab 可调节 NSG 小鼠中由人类造血干细胞重建的人类细胞的免疫反应。 | ||||
| GC69453 | MethADP triammonium | - | >99.00% | |
MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium 是一种 CD73 抑制剂。MethADP 可用于 ATP-腺苷通路的研究。 | ||||
| GC69512 | Muromonab | 140608-64-6 | >98.00% | |
Muromonab 是一种靶向 CD3 受体的单克隆抗体。Muromonab 可以阻断所有细胞毒性 T 细胞功能。Muromonab 也作为一种免疫抑制剂用于减少急性实体器官移植排斥反应。 | ||||
| GC69894 | Siplizumab | 288392-69-8 | - | |
Siplizumab (MEDI-507) 是一种抗 CD2 的人源化 IgG1 单克隆抗体。Siplizumab 可耗尽 T 细胞、降低 T 细胞活化、抑制 T 细胞增殖并富集 naÏve 和 bona fide 调节性 T 细胞。 | ||||
| GC69985 | Talquetamab | 2226212-40-2 | >96.00% | |
Talquetamab(JNJ-64407564)是一种人源化的双特异性抗体,可与 GPRC5D (G 蛋白偶联受体家族C5组成员 D) 和 CD3 结合,通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab(JNJ-64407564)具有抗肿瘤活性。 | ||||
| GC70011 | Teplizumab | 876387-05-2 | >99.00% | |
Teplizumab (MGA-031) 是一种 Fc 受体型、非结合类型的抗-人 CD3 的单克隆抗体。Teplizumab 可缓解 β 细胞的功能丧失。Teplizumab 可用于 type 1 型糖尿病的研究。 | ||||
| GC72342 | Otelixizumab | 881191-44-2 | >99.00% | |
Otelixizumab(ChAglyCD3)是一种抗人CD3单克隆抗体,可用于1型糖尿病的研究。 | ||||
| GC72443 | Pavurutamab | 2250292-39-6 | >95.00% | |
Pavurutamab (AMG-701)是一种抗cd3和抗b细胞成熟抗原(BCMA)的双特异性T细胞接合分子。 | ||||
| GC73334 | Glutaminyl cyclases-IN-1 | 3032400-33-9 | >98.00% | |
Glutaminyl cyclases-IN-1(IsoQC-IN-1)是一种强效的谷氨酰胺环化酶(QC)抑制剂,对人类QC和IsoQC的IC50值分别为12 nM和73 nM。 | ||||
| GC73846 | MA3 aptamer sodium | - | >95.00% | |
MA3 aptamer sodium是一个86碱基长的DNA适体,靶向粘蛋白MUC1。 | ||||
| GC73849 | Ac5GalNTGc | - | >98.00% | |
Ac5GalNTGc是己糖胺的类似物。 | ||||
| GC73850 | Ac5GalNTGc epimer | 1334320-77-2 | >98.00% | |
Ac5GalNTGc epimer是己糖胺的类似物和Ac5GalNTGc的外消旋体。 | ||||
| GC74428 | Anzurstobart | 2543693-10-1 | >98.00% | |
Anzurstobart (cc - 95251;BMS-986351)是一种高亲和力的全人源单克隆抗SIRPα抗体,可阻断CD47与SIRPα的结合。 | ||||
| GC74449 | Vonsetamig | 2408319-33-3 | >95.00% | |
Vonsetamig是一种人源免疫球蛋白G4-kappa,抗tnfrsf17和CD3E单克隆抗体。 | ||||
